PharmaBlock Sciences Nanjing Inc
SZSE:300725

Watchlist Manager
PharmaBlock Sciences Nanjing Inc Logo
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Watchlist
Price: 32.55 CNY 0.37%
Market Cap: 6.5B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one PharmaBlock Sciences Nanjing Inc stock under the Base Case scenario is 38.59 CNY. Compared to the current market price of 32.55 CNY, PharmaBlock Sciences Nanjing Inc is Undervalued by 16%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
38.59 CNY
Undervaluation 16%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.7
P/S
P/S
Price to Sales
3.7
vs History
88
vs Industry
28
Median 3Y
5.2
Median 5Y
10.8
Industry
2.4
Forward
3.1
More Details
31.5
P/E
P/E
Price to Earnings
31.5
vs History
84
vs Industry
11
Median 3Y
37.1
Median 5Y
46.8
Industry
20.5
Forward
25.7
More Details
13
P/OCF
P/OCF
Price to OCF
13
vs History
96
vs Industry
18
Median 3Y
31.8
Median 5Y
68.3
Industry
15.6
More Details
48.4
P/FCFE
P/FCFE
Price to FCFE
48.4
vs History
39
vs Industry
32
Median 3Y
7.3
Median 5Y
10.8
Industry
23.1
More Details
2.2
P/B
P/B
Price to Book Value
2.2
vs History
88
vs Industry
31
Median 3Y
3.1
Median 5Y
6.3
Industry
2
More Details
3.7
EV/S
EV/S
Enterprise Value to Sales
3.7
vs History
90
vs Industry
25
Median 3Y
5.4
Median 5Y
11.1
Industry
2.5
Forward
3.1
More Details
10.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.9
vs History
82
vs Industry
16
Median 3Y
13.3
Median 5Y
24
Industry
4.9
More Details
28.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
28.9
vs History
84
vs Industry
8
Median 3Y
40.6
Median 5Y
57.9
Industry
12.3
Forward
14.1
More Details
28.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
28.9
vs History
84
vs Industry
10
Median 3Y
40.6
Median 5Y
57.9
Industry
15.5
More Details
13
EV/OCF
EV/OCF
Enterprise Value to OCF
13
vs History
96
vs Industry
16
Median 3Y
32.4
Median 5Y
68.1
Industry
14.1
More Details
17.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
17.4
vs History
49
vs Industry
12
Median 3Y
-32.4
Median 5Y
17.4
Industry
17.5
More Details
2
EV/IC
EV/IC
Enterprise Value to IC
2
vs History
80
vs Industry
35
Median 3Y
2.5
Median 5Y
5.6
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
PharmaBlock Sciences Nanjing Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
PharmaBlock Sciences Nanjing Inc
SZSE:300725
6.5B CNY 3.7 31.5 28.9 28.9
US
Eli Lilly and Co
NYSE:LLY
707.1B USD 14.4 63.7 34.3 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
357.1B USD 4 16.4 12 15.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.7 19.3 12.7 14.5
CH
Roche Holding AG
SIX:ROG
206B CHF 3.4 24.9 9.4 10.9
CH
Novartis AG
SIX:NOVN
176.5B CHF 3.9 16.3 9.7 13
UK
AstraZeneca PLC
LSE:AZN
157.8B GBP 3.8 27 131.5 198.3
US
Merck & Co Inc
NYSE:MRK
192.8B USD 3 11.1 8.3 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
130B USD 2.1 16.5 7.2 10.1
P/E Multiple
Earnings Growth PEG
CN
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Average P/E: 25.2
31.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
63.7
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.4
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.3
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.9
32%
0.8
CH
Novartis AG
SIX:NOVN
16.3
17%
1
UK
AstraZeneca PLC
LSE:AZN
27
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.1
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.5
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Average EV/EBITDA: 396.5
28.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.3
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
9.7
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
131.5
9%
14.6
US
Merck & Co Inc
NYSE:MRK
8.3
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Average EV/EBIT: 1 699.7
28.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.4
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.7
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.5
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
13
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
198.3
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 254,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.